Skip to main content

Posts

Showing posts from January 30, 2026

The effect of #NPIs on #influenza throughout the #COVID19 #pandemic: an 8-year interrupted time series study

  Abstract Limited information is available on the impact of non-pharmaceutical interventions (NPIs) and immune debt on influenza during COVID-19 . This retrospective population-based research examined the effect of the COVID-19 pandemic on the prevalence of influenza-like illness (ILI) cases and influenza positive cases in Sichuan Province . Interrupted time series analysis (ITS) was conducted using data gathered from surveillance hospitals throughout 21 cities , including information on patients diagnosed with ILI and positive nucleic acid testing. Subsequent to the implementation of NPIs, there was a notable temporary reduction in both the incidence of ILI cases and confirmed influenza cases, decreasing by 94.7% and 98.0%, respectively (P<0.001). The weekly trend in influenza-positive cases was notable (+4.1%/week, P=0.001). Following the execution of the second-phase intervention, the fluctuations in the transient changes of ILI patients and influenza-positive cases varied ;...

Subclade K #influenza A #H3N2 viruses display partial immune #escape with preserved cross-neutralisation in a #UK population

  Abstract We examined whether the recent emergence of influenza A(H3N2) subclade K, associated with an unusually early influenza season in the Northern hemisphere, was accompanied by a reduction in human population immunity . Using virus neutralisation assays on pre-epidemic human sera collected in May 2025, we found evidence of moderate antigenic drift . Further, vaccines used in the 2024/2025 season induced cross-neutralising immunity . These findings provide timely insight for interpreting recent influenza epidemiology and informing vaccine strain selection. Competing Interest Statement The following authors declare no conflict of interests: KD, RI, LM, SR, HC, GGA, MSA, VS, ZW, SKW, JZ, BJW, DLR, JH, OML, JG, CJRI. PRM receives funding for research work for MSD. EH has received an honorarium for advisory board work for Seqirus. ET has received funding from Novavax and Astra Zeneca. Funding Statement This work was funded by the Medical Research Council (MRC) to the MRC-Universi...

A lethal mouse #model of #Oz virus #infection reveals hepatic involvement and enables evaluation of #antiviral and #vaccine efficacy

  Abstract Oz virus (OZV), a member of the genus Thogotovirus in the family Orthomyxoviridae, is an emerging tick-borne virus reported in Japan . A fatal human case and seroepidemiological evidence of widespread exposure among wild animals and humans suggest its potential public health significance . However, no animal models suitable for pathogenic studies or evaluation of countermeasures are available for OZV. Here, we have established a lethal mouse model of OZV infection using cell-adapted virus and mice lacking type I interferon signaling (B6 Ifnar1 KO mice). OZV infection resulted in 100% mortality and was characterized by robust viral replication in the liver and spleen, severe hepatitis, and acute liver injury . Using this model, we also demonstrated that oral administration of T-705 , an antiviral drug widely used against RNA viruses, as well as immunization with an inactivated whole virus particle vaccine, protected B6 Ifnar1 KO mice from lethal OZV infection by mitigatin...